Hypothyroidism in the older population
Thyroid Research volume 12, Article number: 2 (2019)
Both overt hypothyroidism as well as minor elevations of serum thyrotropin (TSH) levels associated with thyroid hormones within their respective reference ranges (termed subclinical hypothyroidism) are relatively common in older individuals. There is growing evidence that treatment of subclinical hypothyroidism may not be beneficial, particularly in an older person. These findings are relevant at a time when treatment with thyroid hormones is increasing and more than 10–15% of people aged over 80 years are prescribed levothyroxine replacement therapy.
The prevalence of hypothyroidism increases with age. However, the reference range for TSH also rises with age, as the population distribution of TSH concentration progressively rises with age. Furthermore, there is evidence to suggest that minor TSH elevations are not associated with important outcomes such as impaired quality of life, symptoms, cognition, cardiovascular events and mortality in older individuals. There is also evidence that treatment of mild subclinical hypothyroidism may not benefit quality of life and/or symptoms in older people. It is unknown whether treatment targets should be reset depending on the age of the patient. It is likely that some older patients with non-specific symptoms and incidental mild subclinical hypothyroidism may be treated with thyroid hormones and could potentially be harmed as a result. This article reviews the current literature pertaining to hypothyroidism with a special emphasis on the older individual and assesses the risk/benefit impact of contemporary management on outcomes in this age group.
Current evidence suggests that threshold for treating mild subclinical hypothyroidism in older people should be high. It is reasonable to aim for a higher TSH target in treated older hypothyroid patients as their thyroid hormone requirements may be lower. In addition, age-appropriate TSH reference ranges should be considered in the diagnostic pathway of identifying individuals at risk of developing hypothyroidism. Appropriately designed and powered randomised controlled trials are required to confirm risk/benefit of treatment of subclinical hypothyroidism in older people. Until the results of such RCTs are available to guide clinical management international guidelines should be followed that advocate a conservative policy in the management of mild subclinical hypothyroidism in older individuals.
The population of the world is ageing. In the United Kingdom, nearly one in seven people is projected to be aged over 75 years by the year 2040.  However, increases in health life expectancy measured at 65 and 85 are not keeping pace with improvements in numerical life expectancy. This suggests that real health improvements are being experienced by younger people, and that people over 65 years of age are spending more time in ill-health. Therefore, unless this trend can be reversed, a major challenge for an ageing population is likely to be an increasing prevalence of the health conditions associated with old age such as dementia, type 2 diabetes mellitus and cardiac diseases. Apart from the effects on individuals and their families, this demographic change will have major socioeconomic and political implications.
Thyroid hormones have a major influence on all major organs/systems and adequate levels are important for optimal function. Thyroid dysfunction is a common condition that affects between 3 and 21% of the population with prevalence being more common in women and in older individuals.  In the UK, it is estimated that hypothyroidism treated with levothyroxine may affect nearly 800,000 older individuals aged more than 70 years.  The clinical presentation of thyroid dysfunction is non-specific and often variable; therefore, the diagnosis of thyroid dysfunction is based primarily on biochemical abnormalities. The pituitary hormone thyrotropin (TSH) has a complex inverse relationship with the thyroid hormones thyroxine (T4) and tri-iodothyronine (T3). A negative feedback mechanism exists between TSH and thyroid hormones, which means that TSH levels are the most sensitive marker of thyroid status in an individual.  Accordingly, overt hypothyroidism is defined as serum TSH concentrations above the reference range with low free T4 levels, while subclinical hypothyroidism is diagnosed when TSH levels are high and circulating free T4 is normal. The relationship between TSH and thyroid hormones is influenced by a number of factors including age, smoking and thyroid peroxidase antibody status.  Recent data from observational studies suggest that serum TSH levels increase in older people.  Thus, very mild TSH elevations in older individuals may not reflect subclinical thyroid dysfunction but rather be a normal consequence of ageing. Besides, serum TSH levels are also influenced by genetic, environmental, clinical and therapeutic factors and agents, as well as trends in clinical practice . Despite this, adult patients are often managed similarly utilising a uniform serum TSH reference range (usually 0.4–4.5 mU/L) and age-specific ranges are not in routine clinical use. In addition, thyroid hormone requirements change with age and older patients on replacement therapy are more susceptible to the effects of thyroid hormone excess such as osteoporosis and atrial fibrillation. Therefore, careful consideration is required in the interpretation of thyroid function test results as well as in managing thyroid disease in the older population. The interest in thyroid function in the elderly has been increasing with the recognition that thyroid status is may be linked to disability, cognitive function, cardiovascular disease risk and longevity.
This review describes the prevalence of hypothyroidism in the older population and outlines the effects of treatment in this age group.
Prevalence of hypothyroidism in the elderly
Hypothyroidism is more prevalent in older individuals. The Whickham survey was the first population-based study to evaluate the presence of thyroid dysfunction in community-dwelling individuals. This seminal study observed that TSH levels increased with age in women after the age of 45 years but the same phenomenon was not seen in men.  The main limitation of the Whickham study, however, was that it utilised the first-generation TSH assay available at that time and was therefore unable to reliably detect TSH levels lower than 1.0 mU/L. Subsequently, a number of cross-sectional studies have been performed across various geographical locations and studying various age groups. In the studies restricted to older persons, the reported prevalence of overt hypothyroidism has ranged between 0.2–5.7% and subclinical hypothyroidism between 1.5–12.5%. [9,10,11,12,13,14,15,16,17,18,19,20] Some of the main prevalence studies are outlined in Table 1. The wide variation between the various studies probably reflects the disparate nature of the populations being assessed with regards to their gender, iodine intake, age-groups, racial groups and treated thyroid disease prevalence. For example, the Zoetermeer study from the Netherlands reported the lowest prevalence of subclinical hypothyroidism of just 1.5%, most likely due to the inclusion of only men in this analysis. 
As the TSH distribution and the reference limits shift to higher concentrations with age, the prevalence of subclinical hypothyroidism may be overestimated. Employing a uniform TSH reference range across all age groups in the NHANES study led to approximately 70% of older individuals with a slightly high serum TSH being incorrectly classed as having subclinical hypothyroidism.  An analysis of TSH results from one pathology centre in Western Australia however concluded that the use of age-specific TSH reference ranges has minimal impact on reclassifying thyroid status except in the very old (85 years), in whom 2–4.7% were reclassified as being euthyroid.  The reference ranges for TSH are discussed in the next section in more detail.
TSH reference range in the elderly
Biochemical testing of thyroid function is fundamental to establish a diagnosis of thyroid dysfunction including hypothyroidism. The tests include measurement of circulating TSH and thyroid hormones in the serum. Assays for estimating serum TSH have improved vastly over the last few decades and the current immunoassays have the ability to detect very low levels (less than 0.1 mU/L). On the other hand, the reference range for thyroid hormones is wide for a given population, therefore, in principle, TSH will be the first detected circulating abnormality as the pituitary registers that T4 has changed from its genetically determined setpoint for that particular individual.  Thus, TSH measurement has now been firmly established as the first-line thyroid function test to assess thyroid status in the vast majority of patients with suspected thyroid disease. [25, 26] However, it is important to remember that measurement of serum TSH is only reliable for diagnosing thyroid function abnormalities provided that patients are not receiving drug therapies that alter TSH secretion or have pituitary disease. Measurement of serum TSH is also considered to be the key thyroid function test for diagnosing early (also called mild or subclinical) hypo- or hyperthyroidism because of the log-linear relationship between TSH and T4: a twofold change in serum FT4 level leads to a 100-fold alteration in circulating TSH. 
The American National Academy of Clinical Biochemistry formulated guidelines in 2003 which state that “TSH reference intervals should be established from the 95% confidence limits of the log-transformed values of at least 120 rigorously screened normal euthyroid volunteers who have: (a) No detectable thyroid autoantibodies, TPOAb or TgAb (measured by sensitive immunoassay); (b) No personal or family history of thyroid dysfunction; (c) No visible or palpable goitre and, (c) Who are taking no medications except oestrogen”.  In addition, TSH secretion has a diurnal variation with a peak late at night/early hours of morning, and, therefore, sample timing and shift work should also be considered when defining the TSH reference range.  In the last few decades, the ability of the TSH assays to detect lower levels has improved with each generation and therefore the present lower euthyroid reference limit is set at 0.3–0.5 mU/L. This has resulted in subclinical hyperthyroidism being diagnosed with much greater precision, irrespective of the population being studied or the method used. In contrast, the upper (97.5 percentile) reference limit for nonpregnant adults is still not universally agreed. [30, 31] As a consequence, the diagnosis of subclinical hypothyroidism is still very much dependent on the value at which the upper limit of TSH is set.
The TSH reference range should also consider the intra-individual variability of the TSH measurement. Several studies provide data showing significant variation in repeated TSH measurements over time in the same individuals.  Each person has a specific and unique setpoint for thyroid hormone concentrations, which is partly genetically determined, as shown by twin studies.  TSH measurements in an individual vary within 50% of the entire group’s TSH distribution, with a large and clinically significant variation.  TSH levels are also known to increase with age when checked over many years. In both the Cardiovascular Health Study as well as the Busselton Health study, there was a significant rise in TSH levels with little or no change in FT4 levels over a 13-year period. [33, 34] This finding, however, was not confirmed in the Rotterdam study in which TSH levels remained stable over a 6.5-year interval whereas FT4 levels increased.  An analysis from the Baltimore Longitudinal Study of Aging has revealed that changes in thyroid function tests are common, especially in older age groups, and regression to the mean is partly responsible for this finding. Importantly, changes in both TSH and FT4 over a 7-year period were associated with increased mortality. 
The most robust data determining the TSH reference range was obtained from the US National Health and Nutritional Examination Survey (NHANES) III study.  This large study (n = 16,088), designed to be representative of the US general population, analysed the median and lower and upper reference limits of serum TSH in carefully selected euthyroid individuals using current immunoassays. This study concluded that establishing an accurate TSH upper limit at an individual level from population data is not possible, as TSH has a low individuality index (the ratio between the within- and between-person variability). The overall reference range was deemed to be 0.4–4.1 U/L but there were significant differences between age groups and races. For example, the upper limit of TSH was 3.5 mU/L in the 20–29-year olds but increased to 7.9 mU/L in the 80+ year group. Similarly, the upper TSH level was 4.2 mU/L in White people whereas it was 3.4 mU/L in Black people. Similar data obtained from a Scottish laboratory database confirms an age-related increase in the upper reference limit for serum TSH).  An illustration of age-specific TSH reference ranges are described in the Fig. 1.
Serum TSH is not normally distributed and has a skew to the right. However, more than 95% of healthy euthyroid individuals have serum TSH values between 0.4 and 2.5 mU/L. It is therefore argued that TSH values > 2.5 mU/L reflect underlying autoimmune thyroid disease and contribute to the skewed TSH distribution curve,  a view further supported by the fact that such individuals have a higher risk of progression to subsequent hypothyroidism. [39, 40] The opposing argument to retain the upper limit of the TSH reference range around the 4.0–5.0 mU/L mark is that reducing the upper TSH reference limit would lead to a vast increase in the number of people diagnosed with subclinical hypothyroidism without any evidence-based justification or proof of benefits of treatment.  This issue is complicated by the concern that current TSH immunoassays differ in specificity for recognizing circulating TSH isoforms and that this can give rise to a full 1.0 mU/L difference in TSH values reported by different assays.
In summary, the current upper limit of the serum TSH reference range in older people does not reflect age-related changes and leads to the over-diagnosis of hypothyroidism and, consequentially, the probable unnecessary treatment of an unknown number of people with thyroid hormones. The adoption of a universal TSH range across all adult age groups on an individual’s health have not been tested in prospective trials, and unnecessary treatment will lead to a higher health and economic burden. In addition, a slightly higher serum TSH level may be normal in older individuals and not associated with worse outcomes. [18, 33] This has implications for diagnosing subclinical hypothyroidism in the elderly and also the level of serum TSH to aim for in treated hypothyroid patients in this age group.  Therefore, it has been suggested that age-specific reference limits should be utilised instead.  However, further research is required before age-specific TSH reference ranges become part of routine clinical practice.
Consequences of overt and subclinical hypothyroidism in the elderly
The presentation of overt hypothyroidism in the older person is varied, non-specific, and often insidious. The classic symptoms of hypothyroidism are less likely to be evident in the elderly population, and if present, these symptoms are more likely to be misattributed to either co-morbid conditions or a manifestation of the ageing process.  Older people with hypothyroidism report fewer symptoms compared to younger counterparts. [44, 45] A prospective study comparing the frequency of reported symptoms has indicated that hypothyroid patients ≥70 years are significantly less likely to report weight gain, muscle cramps or cold intolerance than hypothyroid patients < 50 years of age.  A study comparing patients with overt autoimmune hypothyroidism against matched euthyroid controls found that whilst younger patients were more likely to report all 13 of the surveyed symptoms of hypothyroidism than their euthyroid controls, for older patients only three of the thirteen symptoms (tiredness, shortness of breath, wheezing) were more prevalent in the hypothyroid group than in the control group. The study used receiver operating characteristic (ROC) analyses to assess the discriminatory ability of a symptom score in the prediction of hypothyroidism, and whilst they identified that this was an excellent tool for predicting hypothyroidism in young men (with an area under the ROC curve of 91%; 95% CI 82–99.8%), it was poor in evaluating older women (area under the ROC curve of 64%; 95% CI 54–75%).  The non-specific and subtle presentation of hypothyroidism in older people is further evidenced by the studies into the screening for hypothyroidism in the older population, which have shown only a minority of patients with confirmed biochemical overt hypothyroidism have symptoms suggestive of the disease. [46, 47]
Whilst it is apparent that for most older patients the presentation of hypothyroidism is both more subtle and less discriminatory than in younger populations, there is however also an increased risk of the most severe presentation of hypothyroidism in the population: myxoedema coma.  Manifesting with multisystem failure with clinical features including reduced consciousness, hypothermia, hypotension, bradycardia, hyponatremia, hypoglycaemia, and hypoventilation, this is a condition with very high morbidity and mortality. However, myxoedema coma is a rare manifestation of hypothyroidism: an analysis of a Japanese national inpatient database estimated an annual incidence of 1.08 per million population.  Symptoms are largely absent or very subtle in older patients with subclinical hypothyroidism. In the subclinical hypothyroid group as a whole, most patients are asymptomatic or report only non-specific symptoms. [49, 50]
Thus, symptoms of hypothyroidism are sparse and non-specific in older people. This leads to thyroid function tests being frequently requested. However, due to the uniform TSH reference range being applied across all age groups, a substantial number of individuals are being detected with mild subclinical hypothyroidism. The median level of TSH at which treatment with thyroid hormones is being commenced has been falling recently although the evidence of benefit is sparse. 
The cardiovascular system is a major target of thyroid hormone action and sensitive to small changes in thyroid hormone concentrations.  A number of observational studies have suggested that even slight reductions in thyroid hormones are associated with higher risk of cardiovascular disease. 
Meta-analyses of observational studies have shown that subclinical hypothyroidism is related to an increased risk of ischaemic heart disease only in younger individuals and not in older populations. [54, 55] However, an individual patient meta-analysis of more than 55,000 participants contributing more than 500,000 person-years of follow-up concluded that age does not influence the relationship between subclinical hypothyroidism and coronary heart disease events nor mortality. 
Thyroid hormones have an inotropic effect on cardiac muscle.  Accordingly, some studies have shown a positive association between hypothyroidism and heart failure.  An individual participant data meta-analysis of 25,390 participants revealed that both low as well as high serum TSH levels.  In stratified analysis, there was a trend towards lower risk of heart failure in older individuals with subclinical hypothyroidism although this did not reach statistical significance.
The relationship between hypothyroidism and stroke has not been completely elucidated. A meta-analysis of individual participant data obtained from nearly half a million person-years of follow up demonstrated no overall effect of subclinical hypothyroidism on stroke although a significantly higher risk was observed in participants younger than 65 years and those with higher serum TSH levels. 
In a longitudinal analysis of participants from the Rotterdam study, the risk of sudden cardiac death was found to be higher with higher FT4 levels, even within the reference range.  In age-stratified analysis, the risk of sudden cardiac death appeared to be particularly higher in older individuals (> 65 years) with higher FT4 levels or lower TSH concentrations.
Older individuals (> 65 years) with subclinical or overt hypothyroidism were not observed to have adverse cardiovascular risk factors such as higher body mass index, increased LDL cholesterol, and prevalence of hypertension or diabetes mellitus in the Cardiovascular Health Study. 
The relationship between overt hypothyroidism and cognitive impairment, depression and other psychiatric manifestations has been long-considered. The term ‘myxoedema madness’ was coined to describe the constellation of confusion, disorientation and psychosis that was observed to occasionally accompany profound hypothyroidism.  These early observations were later supplemented by physiological studies which showed alterations in electroencephalograms, cerebral blood flow, and visual evoked potentials in hypothyroid patients. [60, 61] Hypothyroidism has been shown to be associated in non-demented older adults with impairments in a variety of neuropsychological tests of learning, word fluency, visual-spatial abilities, and mental status. [62, 63]
Whilst hypothyroidism has classically been described as a cause of ‘reversible dementia’, there is a lack of evidence to show that there is complete resolution of neurocognitive deficits following treatment of hypothyroidism.  Further research is required to elucidate the potential role of perturbations of thyroid function as a contributor to a dementing process, as many of the studies to date have not been able to adequately address that hypothyroidism, co-morbidity, polypharmacy and alternative causes of dementia are all common in the elderly, and that interpreting the potential interplay between these factors is complex. 
In subclinical hypothyroidism, a number of studies have shown association with adverse cognitive function in younger individuals, [66,67,68] but results in older people have been conflicting. One study in individuals with a mean age of 74 years showed that people with subclinical hypothyroidism had worse performance on verbal recall and cognitive scores but working memory and processing speed were unaffected.  The PAQUID survey of individuals aged 65 years or more showed that increased TSH levels were significantly linked with the presence of symptoms of depression but not with impairment of cognitive function.  There have been other studies which do not support any association between subclinical hypothyroidism and cognitive impairment. [20, 62, 71, 72] The InCHIANTI study found a significant association between subclinical hyperthyroidism and cognitive impairment as assessed by the mini-mental state examination, but no such association with subclinical hypothyroidism.  A prospective observational study within the Leiden 85+ cohort, which followed up a total of 599 patients from the age of 85 to 89 years for a mean period of 3.7 years, found no significant association between thyroid dysfunction and either depression or cognitive impairment. This was a large and appropriately powered study, and the authors argue that in this very elderly cohort, whilst depression, dementia and thyroid dysfunction are all relatively common, the relationship appears coincidental rather than causal.  In contrast, in a notably younger cohort of predominantly euthyroid patients aged 49–71 years, a higher TSH level was associated with poorer performance in tests of memory.  Amongst the many as-yet unanswered questions about the relationship between thyroid status and cognitive ability, includes the possibility that the nature of this relationship changes with the aging process.
Studies which have addressed whether cognitive functioning improves with levothyroxine therapy in the context of subclinical hypothyroidism have returned conflicting results. Two small randomised controlled trials, recruiting between 19 and 37 patients respectively, have reported improvements in cognitive function with thyroid replacement therapy in subclinical hypothyroidism. [73, 74] However, two larger randomised controlled trials, including the Birmingham elderly thyroid study which enrolled 94 patients over the age of 65 years, showed no improvement with therapy. [49, 75]
Mobility and frailty
Higher TSH levels and subclinical hypothyroidism have been associated with a variety of improved health outcomes in the elderly population, including in domains pertinent to the considerations of mobility and frailty. Amongst the very elderly, there is evidence from the Newcastle 85+ study that lower TSH levels correlate with an increasing burden of nonthyroidal disease and disability.  Indeed, there is evidence from the Health ABC study suggestive of health benefits for older patients whose TSH levels lie within the subclinical hypothyroid range, as in this elderly cohort (mean age 75 years), those with a TSH (4.5–6.99 mU/L) had faster gait speed and superior cardiorespiratory fitness than those with lower TSH levels.  The Leiden 85+ study found no relationship between the serum TSH or fT4 and limitations to activities of daily living in people over the age of 85 years.  In the Zoetermeer study, a longitudinal population study of independent ambulatory predominantly euthyroid men, lower T4 and T3 levels were associated with improved physical functional status.  Quality of life assessment scores have been shown not to differ between the euthyroid and subclinical hypothyroid groups in an elderly population. 
There is relatively scant evidence on the effects of subclinical hypothyroidism on bone health. A Japanese study which employed quantitative heel ultrasound reported that although subclinical hypothyroidism does not appear to affect bone turnover there was an observed impact on bone structure.  The MrOS study found no association between TSH and bone loss as measured by sequential hip dual-energy X-ray absorptiometry, nor an increased fracture risk in the subclinical hypothyroid or hypothyroid categories.  An American prospective observational study which followed up a cohort of 3567 people over the age of 65 years for a median duration of 13 years found that subclinical hypothyroidism was significantly associated with increased risk of hip fracture in men with a hazard ratio of 2.31 (95% CI, 1.25–4.27) but not women. 
In summary, there is little evidence in the literature to clearly link overt hypothyroidism with reduced mobility or increased frailty, and in subclinical hypothyroidism there is some published data suggestive of improvements in these domains compared to euthyroid individuals, although the data is conflicting here.
As the proportion of older people worldwide is increasing rapidly, the factors associated with healthy ageing have become the focus of intense research. Several theories have connected ageing with energy metabolism. One such proposed mechanism relates the lifespan of an organism with its size due to variation in resting metabolic rate. Another theory proposes that increases in free radicals that are generated due to oxidative metabolism are associated with the negative effects of ageing.  Thyroid hormones, via its effects on metabolism and the oxidative stress pathways, play a crucial role in the process of ageing and longevity. Experimental data effectively demonstrate the correlation between thyroid hormones and lifespan. Animal models of longevity, either naturally long-living or genetically modified, demonstrate low thyroid hormone. [81, 82] Age-related mild hypofunction of the thyroid gland seems to confer a longevity benefit. Numerous population-based studies have shown either a survival benefit, [16, 19, 83,84,85] or no adverse impact of lower thyroid function. 
As thyroid hormones have a direct impact on the metabolic rate of an individual and can thus play a key role in modulating longevity it is possible that thyroid hormone replacement in older hypothyroid individuals needs to be tailored differently to that of younger patients. However, the target TSH and thyroid hormone levels are uniform across the age groups and age-specific ranges are not utilised. This is despite the fact that the oldest age groups comprise the largest proportion of all hypothyroid.  Furthermore, over-treatment with thyroid hormones is common in older women, which is a risk factor for atrial fibrillation and osteoporosis.  In the United Kingdom, areas with higher levothyroxine prescribing are independently associated with atrial fibrillation.  No definitive trial of levothyroxine treatment in elderly hypothyroid patients comparing different TSH target values is currently available. A feasibility trial of manipulating thyroid hormone doses in older hypothyroid patients aiming for a higher serum TSH level concluded that a definitive trial is viable. 
Treatment of hypothyroidism in the elderly
Despite the high prevalence of hypothyroidism, there have only been a few RCTs that have investigated outcomes with levothyroxine replacement. Three small RCTs in middle aged individuals with subclinical hypothyroidism showed improvement in cognitive function with levothyroxine replacement therapy. [73, 74, 88] Two larger RCTs with longer follow up have not shown any benefit in cognition with levothyroxine replacement, with the latter study specifically being in the elderly population aged 65 years or over. [49, 75]
The dose of levothyroxine that normalises serum TSH level is lower in older patients due to changes in thyroxine turnover with age related reduction in lean body mass.  Other factors such as decreased absorption, concomitant medication use, and other comorbidities could also affect thyroid hormone metabolism. The elderly are more susceptible to the ill-effects of thyroid hormone excess such as AF,  and osteoporotic fractures. [91, 92] Therefore, careful adjustments of levothyroxine dose at regular intervals are required in this population to avoid iatrogenic hyperthyroidism. The largest study to date of 12 months of levothyroxine treatment in subclinical hypothyroidism in older persons concluded that there was no benefit of treatment on quality of life or symptoms.  This double-blind, randomised, placebo-controlled trial of 737 patients older than 65 years with subclinical hypothyroidism demonstrated no significant improvement in the 100-point ThyPRO score (Thyroid-Related Quality of Life Patient-Reported Outcome) with low-dose levothyroxine treatment.  Therefore, in addition to the lower dose requirements related to thyroxine metabolism, based on the current evidence, it is reasonable to raise the target serum TSH up to 6 or 7 mU/L in persons greater than age 70–80 years particularly if they are at risk of cardiac arrhythmias or osteoporotic fractures.
Thyroid hormones have an essential role in the functioning of nearly all tissues in the body at all stages. Thyroid function changes with age and these alterations are more pronounced at both ends of the life span. Current evidence suggests that a slight lowering of thyroid function in older individuals, as evidenced by a marginally raised serum TSH and low normal FT4, may not be associated with an adverse outcome and may, in fact, be beneficial. On the other hand, high thyroid function, as evidenced by a low TSH level needs careful monitoring and treatment considered if there is evidence of end-organ damage (such as osteoporosis or AF), or if serum TSH is suppressed. Despite major advances in our understanding of thyroid function and ecology, mainly due to improvements in assay techniques and high-quality epidemiological studies, several unresolved issues remain. It is currently unclear what the precise underlying mechanisms are behind the changes in thyroid function that are observed in older individuals. Moreover, it is uncertain whether these changes are part of healthy aging or are a bio-marker of underlying disease.
More research is required to fully understand why thyroid function changes in older individuals and whether modulation of thyroid hormones is advantageous for healthy aging and longevity. Mild thyroid hormone deficiency (or subclinical hypothyroidism) is more common in the elderly. But, if it is ‘normal’ and indeed desirable to have a slightly low thyroid function in older people then the current use of uniform reference ranges across all adult ages may need to be revised. Age-specific reference ranges may be required to diagnose thyroid disease with special reference to subclinical thyroid disease as well as to target serum TSH in patients on thyroid hormone replacement. And, in the future, it is possible that manipulation of thyroid function for health and longevity may be routinely practiced.
receiver operating characteristic
thyroid peroxidase autoantibody
Future of an Ageing Population https://www.ageing.ox.ac.uk/files/Future_of_Ageing_Report.pdf. Accessed 10 Dec 2018.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526. https://doi.org/10.1001/archinte.160.4.526.
Ingoe L, Phipps N, Armstrong G, Rajagopal A, Kamali F, Razvi S. Prevalence of treated hypothyroidism in the community: analysis from general practices in north-East England with implications for the United Kingdom. Clin Endocrinol. 2017;87:860–4. https://doi.org/10.1111/cen.13440.
Hadlow NC, Rothacker KM, Wardrop R, Brown SJ, Lim EM, Walsh JP. The relationship between TSH and free T 4 in a large population is complex and nonlinear and differs by age and sex. J Clin Endocrinol Metab. 2013;98:2936–43. https://doi.org/10.1210/jc.2012-4223.
Brown SJ, Bremner AP, Hadlow NC, Feddema P, Leedman PJ, O’Leary PC, et al. The log TSH-free T4 relationship in a community-based cohort is nonlinear and is influenced by age, smoking and thyroid peroxidase antibody status. Clin Endocrinol. 2016;85:789–96. https://doi.org/10.1111/cen.13107.
Aggarwal N, Razvi S. Thyroid and aging or the aging thyroid? An evidence-based analysis of the literature. J Thyroid Res. 2013;2013:481287. https://doi.org/10.1155/2013/481287.
Jonklaas J, Razvi S. Reference intervals in the diagnosis of thyroid dysfunction – time to treat patients and not numbers. Lancet Diabetes Endocrinol. 2019;In Press.
Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol. 1977;7:481–93 http://www.ncbi.nlm.nih.gov/pubmed/598014. Accessed 2 Dec 2018.
Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The aging thyroid. Arch Intern Med. 1985;145:1386. https://doi.org/10.1001/archinte.1985.00360080056006.
Chaker L, van den Berg ME, Niemeijer MN, Franco OH, Dehghan A, Hofman A, et al. Thyroid function and sudden cardiac death. Circulation. 2016;134:713–22. https://doi.org/10.1161/CIRCULATIONAHA.115.020789.
Benseñor IM, Goulart AC, Lotufo PA, Menezes PR, Scazufca M. Prevalence of thyroid disorders among older people: results from the São Paulo Ageing & Health Study. Cad Saude Publica 2011;27:155–161. http://www.ncbi.nlm.nih.gov/pubmed/21340114. Accessed 2 Dec 2018.
Ceresini G, Lauretani F, Maggio M, Ceda GP, Morganti S, Usberti E, et al. Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in chianti study. J Am Geriatr Soc. 2009;57:89–93. https://doi.org/10.1111/j.1532-5415.2008.02080.x.
Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab. 2004;89:3365–70. https://doi.org/10.1210/jc.2003-031089.
Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295:1033. https://doi.org/10.1001/jama.295.9.1033.
Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2005;165:2460. https://doi.org/10.1001/archinte.165.21.2460.
Gussekloo J, van EE, de CAJM, Meinders AE, Frölich M, Westendorp RGJ. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292:2591. https://doi.org/10.1001/jama.292.21.2591.
Wilson S, Parle JV, Roberts LM, Roalfe AK, Hobbs FDR, Clark P, et al. Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. J Clin Endocrinol Metab. 2006;91:4809–16. https://doi.org/10.1210/jc.2006-1557.
Pearce SHS, Razvi S, Yadegarfar ME, Martin-Ruiz C, Kingston A, Collerton J, et al. Serum thyroid function, mortality and disability in advanced old age: the Newcastle 85+ study. J Clin Endocrinol Metab. 2016;101:4385–94. https://doi.org/10.1210/jc.2016-1935.
van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SWJ. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab. 2005;90:6403–9. https://doi.org/10.1210/jc.2005-0872.
De Jongh RT, Lips P, Van Schoor NM, Deeg DJH, Vandenbroucke JP, Rijs KJ, et al. Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur J Endocrinol. 2011;165:545–54. https://doi.org/10.1530/EJE-11-0430.
Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and Antithyroid antibodies in the U.S. population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab. 2007;92:4575–82. https://doi.org/10.1210/jc.2007-1499.
Kahapola-Arachchige KM, Hadlow N, Wardrop R, Lim EM, Walsh JP. Age-specific TSH reference ranges have minimal impact on the diagnosis of thyroid dysfunction. Clin Endocrinol. 2012;77:773–9. https://doi.org/10.1111/j.1365-2265.2012.04463.x.
Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, et al. Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the chianti area study. J Am Geriatr Soc. 2013;61:868–74. https://doi.org/10.1111/jgs.12267.
Hansen PS, Brix TH, Sørensen TIA, Kyvik KO, Hegedüs L. Major genetic influence on the regulation of the pituitary-thyroid Axis: a study of healthy Danish twins. J Clin Endocrinol Metab. 2004;89:1181–7. https://doi.org/10.1210/jc.2003-031641.
Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22:1200–35. https://doi.org/10.1089/thy.2012.0205.
Okosieme O, Gilbert J, Abraham P, Boelaert K, Dayan C, Gurnell M, et al. Management of primary hypothyroidism: statement by the British thyroid association executive committee. Clin Endocrinol. 2016;84:799–808. https://doi.org/10.1111/cen.12824.
Andersen S, Bruun NH, Pedersen KM, Laurberg P. Biologic variation is important for interpretation of thyroid function tests. Thyroid. 2003;13:1069–78. https://doi.org/10.1089/105072503770867237.
Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry J-F, et al. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:3–3. https://doi.org/10.1089/105072503321086962.
Jensen E, Petersen PH, Blaabjerg O, Hansen PS, Brix TH, Kyvik KO, et al. Establishment of a serum thyroid stimulating hormone (TSH) reference interval in healthy adults. The importance of environmental factors, including thyroid antibodies. Clin Chem Lab Med. 2004;42:824–32. https://doi.org/10.1515/CCLM.2004.136.
Dickey RA, Wartofsky L, Feld S. Optimal thyrotropin level: Normal ranges and reference intervals are not equivalent. Thyroid. 2005;15:1035–9. https://doi.org/10.1089/thy.2005.15.1035.
Surks MI, Goswami G, Daniels GH. The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab. 2005;90:5489–96. https://doi.org/10.1210/jc.2005-0170.
Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T 4 and T 3 in Normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab. 2002;87:1068–72. https://doi.org/10.1210/jcem.87.3.8165.
Waring AC, Harrison S, Samuels MH, Ensrud KE, LeBlanc ES, Hoffman AR, et al. Thyroid function and mortality in older men: a prospective study. J Clin Endocrinol Metab. 2012;97:862–70. https://doi.org/10.1210/jc.2011-2684.
Bremner AP, Feddema P, Leedman PJ, Brown SJ, Beilby JP, Lim EM, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab. 2012;97:1554–62. https://doi.org/10.1210/jc.2011-3020.
Mammen JS, McGready J, Ladenson PW, Simonsick EM. Unstable thyroid function in older adults is caused by alterations in both thyroid and pituitary physiology and is associated with increased mortality. Thyroid. 2017;27:1370–7. https://doi.org/10.1089/thy.2017.0211.
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T 4 , and thyroid antibodies in the United States population (1988 to 1994): National Health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489–99. https://doi.org/10.1210/jcem.87.2.8182.
Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the thyroid epidemiology, audit, and research study (TEARS). J Clin Endocrinol Metab. 2013;98:1147–53. https://doi.org/10.1210/jc.2012-3191.
Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab. 2005;90:5483–8. https://doi.org/10.1210/jc.2005-0455.
Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol. 1995;43:55–68. https://doi.org/10.1111/j.1365-2265.1995.tb01894.x.
Walsh JP, Bremner AP, Feddema P, Leedman PJ, Brown SJ, O’Leary P. Thyrotropin and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study of a community-based cohort using current immunoassay techniques. J Clin Endocrinol Metab. 2010;95:1095–104. https://doi.org/10.1210/jc.2009-1977.
Razvi S, Ingoe L, Ryan V, Pearce SHS, Wilkes S. Study of optimal replacement of thyroxine in the elderly (SORTED) – results from the feasibility randomised controlled trial. Thyroid Res. 2016;9:5. https://doi.org/10.1186/s13044-016-0034-x.
Boucai L, Hollowell JG, Surks MI. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid. 2011;21:5–11. https://doi.org/10.1089/thy.2010.0092.
Bensenor I, Lotufo P, Diaz-Olmos PA. Hypothyroidism in the elderly: diagnosis and management. Clin Interv Aging. 2012;7:97. https://doi.org/10.2147/CIA.S23966.
Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Andersen S, et al. Hypothyroid symptoms fail to predict thyroid insufficiency in old people: a population-based case-control study. Am J Med. 2016;129:1082–92. https://doi.org/10.1016/j.amjmed.2016.06.013.
Doucet J, Trivalle C, Chassagne P, Perol M-B, Vuillermet P, Manchon N-D, et al. Does age play a role in clinical presentation of hypothyroidism? J Am Geriatr Soc. 1994;42:984–6. https://doi.org/10.1111/j.1532-5415.1994.tb06592.x.
Bahemuka M, Hodkinson HM. Screening for hypothyroidism in elderly inpatients. Br Med J. 1975;2:601–3. https://doi.org/10.1136/bmj.2.5971.601.
Lloyd WH, Goldberg IJ. Incidence of hypothyroidism in the elderly. Br Med J 1961;2:1256–1259.
Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y. Clinical characteristics and outcomes of myxedema coma: analysis of a national inpatient database in Japan. J Epidemiol. 2017;27:117–22. https://doi.org/10.1016/j.je.2016.04.002.
Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, Jenssen TG. Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. J Clin Endocrinol Metab. 2006;91:145–53. https://doi.org/10.1210/jc.2005-1775.
Javed Z, Sathyapalan T. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. Ther Adv Endocrinol Metab. 2016;7:12–23. https://doi.org/10.1177/2042018815616543.
Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, Greenwood R, et al. Falling threshold for treatment of borderline elevated thyrotropin levels—balancing benefits and risks. JAMA Intern Med. 2014;174:32. https://doi.org/10.1001/jamainternmed.2013.11312.
Razvi S, Jabbar A, Pingitore A, Danzi S, Biondi B, Klein I, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol. 2018;71:1781–96. https://doi.org/10.1016/j.jacc.2018.02.045.
Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76–131. https://doi.org/10.1210/er.2006-0043.
Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148:832–45. https://doi.org/10.7326/0003-4819-148-11-200806030-00225.
Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SHS. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a Metaanalysis. J Clin Endocrinol Metab. 2008;93:2998–3007. https://doi.org/10.1210/jc.2008-0167.
Jabbar A, Pingitore A, Pearce SHS, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2016;14:39–55. https://doi.org/10.1038/nrcardio.2016.174.
Gencer B, Collet T-H, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events. Circulation. 2012;126:1040–9. https://doi.org/10.1161/CIRCULATIONAHA.112.096024.
Chaker L, Baumgartner C, den Elzen WPJ, Ikram MA, Blum MR, Collet T-H, et al. Subclinical hypothyroidism and the risk of stroke events and fatal stroke: an individual participant data analysis. J Clin Endocrinol Metab. 2015;100:2181–91. https://doi.org/10.1210/jc.2015-1438.
Asher R. Myxoedematous madness. Br Med J 1949;2:555–562.
Lansing RW, Trunnell JB. Electroencephalographic changes accompanying thyroid deficiency in Man1. J Clin Endocrinol Metab. 1963;23:470–80. https://doi.org/10.1210/jcem-23-5-470.
Ladenson PW, Stakes JW, Ridgway EC. Reversible alteration of the visual evoked potential in hypothyroidism. Am J Med. 1984;77:1010–4. https://doi.org/10.1016/0002-9343(84)90180-3.
Osterweil D, Syndulko K, Cohen SN, Pettier-Jennings PD, Hershman JM, Cummings JL, et al. Cognitive function in non-demented older adults with hypothyroidism. J Am Geriatr Soc. 1992;40:325–35. https://doi.org/10.1111/j.1532-5415.1992.tb02130.x.
Mennemeier M, Garner RD, Heilman KM. Memory, mood and measurement in hypothyroidism. J Clin Exp Neuropsychol. 1993;15:822–31. https://doi.org/10.1080/01688639308402598.
Clarnette RM, Patterson CJ. Hypothyroidism: does treatment cure dementia? J Geriatr Psychiatry Neurol. 7:23–7. http://www.ncbi.nlm.nih.gov/pubmed/8192826. Accessed 6 Dec 2018.
Dugbartey AT. Neurocognitive aspects of hypothyroidism. Arch Intern Med. 1998;158:1413–8. https://doi.org/10.1001/archinte.158.13.1413.
Monzani F, Guerra P, Caracciol N, Pruneti CA, Puccil E, Luisit M, et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-thyroxine treatment. Clin Investig. 1993;71:367–71. https://doi.org/10.1007/BF00186625.
Baldini IM, Vita A, Mauri MC, Amodei V, Carrisi M, Bravin S, et al. Psychopathological and cognitive features in subclinical hypothyroidism. Prog Neuro-Psychopharmacology Biol Psychiatry. 1997;21:925–35. https://doi.org/10.1016/S0278-5846(97)00089-4.
del Ser Quijano T, Delgado C, Martinez Espinosa S, Vázquez C. [cognitive deficiency in mild hypothyroidism]. Neurol (Barcelona, Spain) 2000;15:193–198.
Cook SE, Nebes RD, Halligan EM, Burmeister LA, Saxton JA, Ganguli M, et al. Memory impairment in elderly individuals with a mildly elevated serum TSH: the role of processing resources, depression and cerebrovascular disease. Aging Neuropsychol Cogn. 2002;9:175–83. https://doi.org/10.1076/anec.184.108.40.20610.
Manciet G, Dartigues JF, Decamps A, Gateau PB, Letenneur L, Latapie MJ, et al. The PAQUID survey and correlates of subclinical hypothyroidism in elderly community residents in the south west of France. Age Ageing. 1995;24:235–41. https://doi.org/10.1093/ageing/24.3.235.
Luboshitzky R, Oberman AS, Kaufman N, Reichman N, Flatau E. Prevalence of cognitive dysfunction and hypothyroidism in an elderly community population. Isr J Med Sci. 1996;32:60–5.
Park YJ, Lee EJ, Lee YJ, Choi SH, Park JH, Lee SB, et al. Subclinical hypothyroidism (SCH) is not associated with metabolic derangement, cognitive impairment, depression or poor quality of life (QoL) in elderly subjects. Arch Gerontol Geriatr. 2010;50:e68–73. https://doi.org/10.1016/J.ARCHGER.2009.05.015.
Jaeschke R, Guyatt G, Gerstein H, Patterson C, Molloy W, Cook D, et al. Does treatment withl-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med. 1996;11:744–9. https://doi.org/10.1007/BF02598988.
Nyström E, Caidahl K, Fager G, Wikkelsö C, Lundberg P-A, Lindstedt G. A double-blind cross-over 12-month study of I-thyroxine treatment of women with “subclinical” Hypothyrodism. Clin Endocrinol. 1988;29:63–76. https://doi.org/10.1111/j.1365-2265.1988.tb00250.x.
Parle J, Roberts L, Wilson S, Pattison H, Roalfe A, Haque MS, et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham elderly thyroid study. J Clin Endocrinol Metab. 2010;95:3623–32. https://doi.org/10.1210/jc.2009-2571.
Simonsick EM, Newman AB, Ferrucci L, Satterfield S, Harris TB, Rodondi N, et al. Subclinical hypothyroidism and functional mobility in older adults. Arch Intern Med. 2009;169:2011–7. https://doi.org/10.1001/archinternmed.2009.392.
Nagata M, Suzuki A, Sekiguchi S, Ono Y, Nishiwaki-Yasuda K, Itoi T, et al. Subclinical hypothyroidism is related to lower heel QUS in postmenopausal women. Endocr J. 2007;54:625–30. https://doi.org/10.1507/ENDOCRJ.K06-201.
Waring AC, Harrison S, Fink HA, Samuels MH, Cawthon PM, Zmuda JM, et al. A prospective study of thyroid function, bone loss, and fractures in older men: the MrOS study. J Bone Miner Res. 2013;28:472–9. https://doi.org/10.1002/jbmr.1774.
Lee JS, Buzková P, Fink HA, Vu J, Carbone L, Chen Z, et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med. 2010;170:1876–83. https://doi.org/10.1001/archinternmed.2010.424.
Jansen SW, Akintola AA, Roelfsema F, van der Spoel E, Cobbaert CM, Ballieux BE, et al. Human longevity is characterised by high thyroid stimulating hormone secretion without altered energy metabolism. Sci Rep. 2015;5:11525. https://doi.org/10.1038/srep11525.
Buffenstein R. The naked mole-rat: a new long-living model for human aging research. Journals Gerontol - Ser A Biol Sci Med Sci. 2005;60:1369–77. https://doi.org/10.1093/gerona/60.11.1369.
Vergara M, Smith-Wheelock M, Harper JM, Sigler R, Miller RA. Hormone-treated snell dwarf mice regain fertility but remain long lived and disease resistant. J Gerontol A Biol Sci Med Sci. 2004;59:1244–50.
Rozing MP, Houwing-Duistermaat JJ, Slagboom PE, Beekman M, Frölich M, de Craen AJM, et al. Familial longevity is associated with decreased thyroid function. J Clin Endocrinol Metab. 2010;95:4979–84. https://doi.org/10.1210/jc.2010-0875.
Ceresini G, Marina M, Lauretani F, Maggio M, Bandinelli S, Ceda GP, et al. Relationship between circulating thyroid-stimulating hormone, free thyroxine, and free triiodothyronine concentrations and 9-year mortality in Euthyroid elderly adults. J Am Geriatr Soc. 2016;64:553–60. https://doi.org/10.1111/jgs.14029.
Yeap BB, Alfonso H, Hankey GJ, Flicker L, Golledge J, Norman PE, et al. Higher free thyroxine levels are associated with all-cause mortality in euthyroid older men: the health in men study. Eur J Endocrinol. 2013;169:401–8. https://doi.org/10.1530/EJE-13-0306.
Mammen JS, McGready J, Oxman R, Chia CW, Ladenson PW, Simonsick EM. Thyroid hormone therapy and risk of thyrotoxicosis in community-resident older adults: findings from the Baltimore longitudinal study of aging. Thyroid. 2015;25:979–86. https://doi.org/10.1089/thy.2015.0180.
Razvi S, Korevaar T, Taylor P. Trends, determinants and associations of treated hypothyroidism in the United Kingdom, 2005 – 2014. Thyroid 2018;:thy.2018.0251. https://doi.org/10.1089/thy.2018.0251.
Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid. 2007;17:249–58. https://doi.org/10.1089/thy.2006.0252.
Rosenbaum RL, Barzel US. Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med. 1982;96:53–5. https://doi.org/10.7326/0003-4819-96-1-53.
Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52. https://doi.org/10.1056/NEJM199411103311901.
Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134:561–8. https://doi.org/10.7326/0003-4819-134-7-200104030-00009.
Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95:186–93. https://doi.org/10.1210/jc.2009-1625.
Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376:2534–44. https://doi.org/10.1056/NEJMoa1603825.
This article was not funded by any specific sources.
Availability of data materials
Data sharing is not applicable to this article as no datasets were generate or analysed during the current study.
Ethics approval and consent to participate
Consent to publication
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.